PaRftZLfx方案在難治性肺結核中的應用效果評價
打開文本圖片集
Evaluation of the Application Efect of PaRftZLfx Regimen in Refractory Pulmonary Tuberculosis/ HUANG Ziqiang， ZHU Jing， ZHANG She， WU Junjie. //Medical Innovation of China， 2025， 22（11）： 144-148
[Abstract]Objective： To explore the value of PaRfZLfx regimen in the treatment of refractory pulmonary tuberculosis.Method：Atotal of 80patients withrefractorypulmonarytuberculosiswereselected， allof whom were admitted to the Department of Lung Disease of Yangzhou Third People's Hospital from February 2022 to October 2023.They were randomly divided into two groups according to the random number method.The control group （40 cases） received LfxEPAS chemotherapy regimen， while the observation group （40 cases）received PaRfZLfx treatment.The clinical eficacy after3 months of treatment，sputumconversionrate after 2， 4，and 6 monthsof treatment，cavityclosure after 6 months oftreatment， incidence ofadverse reactionswithin 3 months，and changes in immune functionafter 3 monthsof treatment were compared.Result：The totaleffctiverate，sputum conversion rate，andcavityclosure intheobservation groupwere allbeterthanthose inthecontrol group，thediffrences were statistically significant （ P <0.05）.The incidence of adverse reactions in the observation group was lower than that in the control group， the difference was statistically significant （ P<0.05 . Compared with before treatment， CD ， CD CD4+/CD8 in both groups increased significantly after 3 months of treatment， while CD decreased significantly， the observation group were superior to the control group，the diferences were statistically significant （ P <0.05）.
Conclusion： Choosing PaRftZLfx in the treatment of refractory pulmonary tuberculosis can improve cavity closure， sputum conversion rate， ensure treatment effectiveness and safety， and enhance immune function.
[Key words] Rifapentine Refractory pulmonary tuberculosis Cavity closure Sputum conversion
First-author's address： Department of Lung Disease， Yangzhou Third People's Hospital， Yangzhou 225125， China
doi：10.3969/j.issn.1674-4985.2025.11.032
肺結核是由結核分枝桿菌感染后引起的肺部慢性傳染性疾病，且為結核病中最常見的一種類型，若肺結核患者在經(jīng)過多次治療之后未得到明顯的治療效果，同時導致肺結核主要的感染菌已經(jīng)對一些常用的藥物產(chǎn)生嚴重的耐藥性，此時可判定為難治性肺結核。（剩余6053字）